Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR6474] to Lipoprotein a
- Suitable for: WB
- Reacts with: Human
Product nameAnti-Lipoprotein a antibody [EPR6474]
See all Lipoprotein a primary antibodies
DescriptionRabbit monoclonal [EPR6474] to Lipoprotein a
Tested applicationsSuitable for: WBmore details
Unsuitable for: Flow Cyt,ICC/IF or IHC-P
Species reactivityReacts with: Human
Synthetic peptide within Human Lipoprotein a aa 150-250. The exact sequence is proprietary.
- WB: Human plasma lysate.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Concentration information loading...
PurityProtein A purified
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Lipoprotein metabolism
Our Abpromise guarantee covers the use of ab125014 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/10000 - 1/50000. Detects a band of approximately 501 kDa (predicted molecular weight: 501 kDa).|
RelevanceLipoprotein(a) (Lp(a)) is a lipoprotein subclass assembled in the blood from low density lipoprotein (LDL) molecules and apolipoprotein-a (apo-a). Lp(a) recruits inflammatory cells through interaction with Mac-1 integrin. High Lp(a) in blood is a risk factor for coronary heart disease, cerebrovascular disease, atherosclerosis, thrombosis, and stroke. Lp(a) concentrations may be affected by disease states, but are only moderately affected by diet, exercise and other environmental factors. Lipid-reducing drugs have no effect on Lp(a) concentration. High Lp(a) predicts risk of early atherosclerosis similar to high LDL, but in advanced atherosclerosis, Lp(a) is a risk factor independent of LDL, indicating a coagulant risk of plaque thrombosis. Apo(a) contains domains that are very similar to plasminogen (PLG). Lp(a) accumulates in the vessel wall and inhibits binding of PLG to the cell surface, reducing plasmin generation which increases clotting. This inhibition also promotes proliferation of smooth muscle cells. These unique features of Lp(a) suggest a role in the generation of clots and atherosclerosis.
- AK38 antibody
- Antiangiogenic AK38 protein antibody
- apo(a) antibody
Anti-Lipoprotein a antibody [EPR6474] (ab125014) at 1/50000 dilution (purified) + Human plasma lysate at 10 µg
HRP-conjugated goat anti-rabbit IgG (specific to the non-reduced form of IgG) at 1/1000 dilution
Predicted band size: 501 kDa
Observed band size: 501 kDa
Blocking and dilution buffer: 5% NFDM /TBST.
The observed bands are consistant with desciption in PMID:10703674, which should be N-terminal fragments.
Anti-Lipoprotein a antibody [EPR6474] (ab125014) at 1/20000 dilution (unpurified) + Human plasma lysate at 10 µg
HRP-conjugated goat anti-rabbit IgG at 1/2000 dilution
Predicted band size: 501 kDa
Observed band size: 500 kDa why is the actual band size different from the predicted?
ab125014 has been referenced in 3 publications.
- Oliveira C et al. Apolipoprotein(a) inhibits hepatitis C virus entry through interaction with infectious particles. Hepatology 65:1851-1864 (2017). PubMed: 28152568
- Raal FJ et al. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. J Lipid Res 57:1086-96 (2016). PubMed: 27102113
- Müller N et al. IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. J Lipid Res 56:1034-42 (2015). PubMed: 25713100